

Prof. ÖZGE GÜMÜŞAY

Personal Information

Email: Ozge.Gumusay@acibadem.edu.tr

Web: <https://avesis.acibadem.edu.tr/Ozge.Gumusay>

International Researcher IDs

ORCID: 0000-0002-6236-9829

Education Information

Post Doctorate of Medicine, Gazi University, Tıp Fakültesi, Turkey 2010 - 2014

Expertise In Medicine, Gazi University, Tıp Fakültesi, Turkey 2006 - 2010

Undergraduate, Hacettepe University, Tıp Fakültesi (İngilizce), Turkey 1999 - 2005

Foreign Languages

English, C1 Advanced

Certificates, Courses and Trainings

Education Management and Planning, Tıp Fakültesi Eğitimci Gelişimi Temel Kursu Katılım Belgesi, Acibadem Mehmet Ali Aydınlar Üniversitesi, 2023

Other, BUS 160 W Leadership Skills for Women in the Workplace: How to Aim High an Achieve Impact, STANFORD UNIVERSITY (Stanford Continuing Studies Program Fall 2020-2021 Courses), 2020

Other, WSP 161 Ketogenic Diets and Intermittent Fasting: Fads, Facts and Fiction, STANFORD UNIVERSITY (Stanford Continuing Studies Program Fall 2020-2021 Courses), 2020

Foreign Language, COM 39 Accent Reduction for Non-Native Speakers of English:, STANFORD UNIVERSITY (Stanford Continuing Studies Program Fall 2020-2021 Courses), 2020

Other, BIO 03 W Diet and Gene Expression: You Are What You Eat: , STANFORD UNIVERSITY (Stanford Continuing Studies Program Fall 2020-2021 Courses), 2020

Health&Medicine, Deney Hayvanları Uygulama ve Etik Kursu, Gazi Üniversitesi, 2013

Dissertations

Expertise In Medicine, Kronik hepatit B hastalarında serum hyaluronik asit, matriks metalloproteinaz-2, doku matriks metalloproteinaz inhibitörü-1 ve prokollajen III N-terminal peptid düzeyinin karaciğer fibrozisini göstermedeki değeri, Gazi University, Tıp Fakültesi, Dahili Tıp Bilimleri, 2010

Research Areas

Oncology

Academic titles / Tasks

Professor, Acibadem Mehmet Ali Aydınlar University, School Of Medicine, Department Of Medical Sciences, 2023 - Continues

Associate Professor, Acibadem Mehmet Ali Aydınlar University, School Of Medicine, Department Of Medical Sciences, 2022 - 2023

Associate Professor, Tokat Gaziosmanpaşa University, School Of Medicine, 2017 - 2020

Assistant Professor, Tokat Gaziosmanpaşa University, School Of Medicine, 2015 - 2017

Research Assistant, Gazi University, Tıp Fakültesi, 2010 - 2014

Research Assistant, Gazi University, Tıp Fakültesi, 2006 - 2010

Academic and Administrative Experience

4. Sınıf İç Hastalıkları Programı Koordinatörü, Acibadem Mehmet Ali Aydınlar University, School Of Medicine, Department Of Medical Sciences, 2023 - Continues

Head of Department, Tokat Gaziosmanpaşa University, School Of Medicine, 2015 - 2019

Courses

Lung cancer:screening, diagnosis, risk factors, principles of therapy, Undergraduate, 2023 - 2024

Review of history taking and physical examination, Undergraduate, 2023 - 2024

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)**
Yasar H. A., Aktas B. Y., Ucar G., Goksu S. S., Bilgetekin I., Cakar B., Sakin A., Ates O., Basoglu T., Arslan C., et al.
Clinical Genitourinary Cancer, vol.22, no.3, 2024 (SCI-Expanded)
- II. **A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer**
Gümüşay Ö., Huppert L. A., Magbanua M. J. M., Wabl C. A., Assefa M., Chien A. J., Melisko M. E., Majure M. C., Moasser M., Park J., et al.
BREAST CANCER RESEARCH AND TREATMENT, vol.203, no.2, pp.197-204, 2024 (SCI-Expanded)
- III. **Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer**
Huppert L. A., Gümüşay Ö., Idossa D., Rugo H. S.
CA-A CANCER JOURNAL FOR CLINICIANS, vol.73, no.5, pp.480-515, 2023 (SCI-Expanded)
- IV. **Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study**
Bilici A., Koca S., Karaagac M., Aydın S. G., Eraslan E., Kaplan M. A., Ocak B., Goksu S. S., Paydas S., Akgul F., et al.
Journal of Cancer Research and Clinical Oncology, vol.149, no.11, pp.8243-8253, 2023 (SCI-Expanded)
- V. **Advancing immunotherapy in gastroesophageal cancer through rational combinations and biomarkers**
Çetin B., Wabl C. A., Gümüşay Ö.
IMMUNOTHERAPY, vol.15, no.12, pp.945-962, 2023 (SCI-Expanded)
- VI. **Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer.**
Kahraman S., Erul E., Seyyar M., Gumusay Ö., Bayram E., Demirel B. C., Acar O., Aksoy S., Baytemur N. K., Sahin E., et al.
Future oncology (London, England), 2023 (SCI-Expanded)

- VII. **252P Impact of HER2 expression levels on survival in patients with hormone receptor positive and HER2 negative advanced breast cancer and treated with ribociclib and palbociclib in combination with endocrine therapy: A real-life data, Turkish Oncology Group study**
Kahraman S., Gümüşay Ö., Başaran G., Çabuk D., Aydın A., Paydaş S., Şendur M. A. N.
ESMO OPEN, vol.8, no.1, pp.1-2, 2023 (SCI-Expanded)
- VIII. **Alpelisib induced interstitial lung disease in a patient with advanced breast cancer**
Isıklar A., Basaran G., Sepin B., Gumusay Ö., Kocagoz A. S., Cuhadaroglu Ç.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.29, no.2, pp.484-488, 2023 (SCI-Expanded)
- IX. **Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer?**
Cetin B., Wabl C. A., GÜMÜŞAY Ö.
FUTURE ONCOLOGY, no.39, pp.4235-4238, 2022 (SCI-Expanded)
- X. **Clinical outcome and characteristics of Turkish breast cancer patients during SARS-Cov-2 pandemic: Single center experience.**
Isıklar A., Soyder A., Gümüşay Ö., Basaran G.
JOURNAL OF CLINICAL ONCOLOGY, vol.40, no.16_suppl, pp.1-5, 2022 (SCI-Expanded)
- XI. **The role of percutaneous vertebral augmentation in patients with metastatic breast cancer: Literature review including report of two cases**
Gumusay Ö., Huppert L. A., Behr S. C., Rugo H. S.
BREAST, vol.63, pp.149-156, 2022 (SCI-Expanded)
- XII. **Emerging treatment strategies for metastatic triple-negative breast cancer**
Huppert L. A., Gumusay Ö., Rugo H. S.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, vol.14, 2022 (SCI-Expanded)
- XIII. **Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management Optimal Management for Renal Cell Cancer Patients**
Cetin B., Wabl C. A., Gumusay Ö.
CURRENT TREATMENT OPTIONS IN ONCOLOGY, vol.23, no.4, pp.609-629, 2022 (SCI-Expanded)
- XIV. **Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy**
Magbanua M. J. M., Gumusay Ö., Kurzrock R., van't Veer L. J., Rugo H. S.
FRONTIERS IN ONCOLOGY, vol.12, 2022 (SCI-Expanded)
- XV. **CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer**
Cetin B., Wabl C. A., Gumusay Ö.
FUTURE ONCOLOGY, vol.18, no.9, pp.1143-1157, 2022 (SCI-Expanded)
- XVI. **Optimal Treatment for Patients with Oligometastatic Prostate Cancer**
Cetin B., Wabl C. A., Gumusay Ö.
UROLOGIA INTERNATIONALIS, vol.106, no.3, pp.217-226, 2022 (SCI-Expanded)
- XVII. **Immunotherapy toxicity: identification and management**
Gumusay Ö., Callan J., Rugo H. S.
BREAST CANCER RESEARCH AND TREATMENT, vol.192, no.1, pp.1-17, 2022 (SCI-Expanded)
- XVIII. **Merkel cell carcinoma in Turkey: A multicentric study**
Yildiz F., Demirci U., Kucukarda A., BÜYÜKŞİMŞEK M., Sakalar T., Topcu T. O., Aslan F., Tufan G., Aydın O., Turna H., et al.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, no.6, pp.1525-1529, 2021 (SCI-Expanded)
- XIX. **Understanding relevant immune mechanisms in gastrointestinal oncology**
Cetin B., Gumusay Ö.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.27, no.5, pp.1222-1234, 2021 (SCI-Expanded)
- XX. **Ezrin is a prognostic biomarker in patients with clear cell metastatic renal cell carcinoma receiving sunitinib**
Cetin B., Gonul I. I., Gumusay Ö., AFŞAR B., Bilgetekin I., ÖZET A., ÜNER A.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, vol.17, no.2, pp.408-413, 2021 (SCI-Expanded)

- XXI. **eNOS and VEGF Variants Might Increase the Risk of Pancreatic Cancer**
DAGMURA H., Yigit S., Gumusay Ö., Nursal A. F., Daldal E., Karakus N.
CYTOLOGY AND GENETICS, vol.55, no.2, pp.177-182, 2021 (SCI-Expanded)
- XXII. **Possible Association of PER2/PER3 Variable Number Tandem Repeat Polymorphism Variants with Susceptibility and Clinical Characteristics in Pancreatic Cancer**
DAGMURA H., Yigit S., Nursal A. F., Duman E., Gumusay Ö.
GENETIC TESTING AND MOLECULAR BIOMARKERS, vol.25, no.2, pp.124-130, 2021 (SCI-Expanded)
- XXIII. **Circulating tumor cell (CTC) enumeration in a phase II trial of pazopanib in addition to endocrine therapy in patients with hormone resistant advanced breast cancer (ABC)**
Gumusay Ö., Magbanua M. J. M., Majure M. C., Deal T., Renslo J. R., Wabl C. A., Melisko M. E., Chien A. J., Goga A., Moasser M. M., et al.
CANCER RESEARCH, no.4, 2021 (SCI-Expanded)
- XXIV. **The DNA damaging revolution**
Cetin B., Wabl C. A., Gumusay Ö.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol.156, 2020 (SCI-Expanded)
- XXV. **Can you draw the picture of happiness- Treatment of a young woman with breast cancer during the COVID-19 pandemic**
Cetin B., RAKICI S., Gumusay Ö.
ASIAN JOURNAL OF PSYCHIATRY, vol.52, 2020 (SCI-Expanded)
- XXVI. **Pembrolizumab for Early Triple-Negative Breast Cancer**
Cetin B., Gumusay Ö.
NEW ENGLAND JOURNAL OF MEDICINE, vol.382, no.26, 2020 (SCI-Expanded)
- XXVII. **Does primary tumor localization has prognostic importance in seminoma patients?: Turkish Oncology Group Study.**
Yildiz B., Kucukarda A., Gokyer A., Gokcen Demiray A., Paydas S., Pinar Aral I., Gumusay Ö., Bilici A., Akdeniz N., Bahceci A., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.25, no.2, pp.1130-1135, 2020 (SCI-Expanded)
- XXVIII. **Failure of Concurrent Chemoradiotherapy for Organ Preservation in Laryngeal Cancer: Survival Outcomes and Recurrence Patterns**
AYDİL U., AKMANSU M., Gumusay Ö., Eravci F. C., Bakkal F. K., Yazici O., KIZIL Y., Zorlu M. E., Yildiz R., Koybasioglu A.
ENT-EAR NOSE & THROAT JOURNAL, vol.98, no.7, 2019 (SCI-Expanded)
- XXIX. **Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes**
Esin E., Oksuzoglu B., Bilici A., ÇİÇİN İ., KÖSTEK O., Kaplan M. A., AKSOY S., AKTAŞ B. E., Ozdemir O., Alacacioglu A., et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.83, no.1, pp.131-143, 2019 (SCI-Expanded)
- XXX. **EGFR Mutation in Patients with NSCLC and Its Relationship Between Survival and Clinicopathological Features: An Update Analysis**
Ozturk A., Celik S., Kodaz H., Yildiz I., Ocak A., Hacibekiroglu I., Bayoglu I. V., Ercelep O., Ekinci A. S., Menekse S., et al.
JOURNAL OF THORACIC ONCOLOGY, no.10, 2018 (SCI-Expanded)
- XXXI. **Carbonic anhydrase IX is a prognostic biomarker in glioblastoma multiforme**
Cetin B., Gonul I. I., Gumusay Ö., Bilgetekin I., Algin E., ÖZET A., ÜNER A.
NEUROPATHOLOGY, vol.38, no.5, pp.457-462, 2018 (SCI-Expanded)
- XXXII. **Merkel cell carcinoma in Turkey: A multicentric study.**
Yildiz F., BÜYÜKŞİMŞEK M., Sakalar T., AYDIN ÜLGEN Ö., TURNA Z. H., Babacan N. A., Yildiz B., Arslan C., Ozdemir N., ÜRÜN Y., et al.
JOURNAL OF CLINICAL ONCOLOGY, no.15, 2018 (SCI-Expanded)
- XXXIII. **Efficiency and safety of regorafenib in metastatic colorectal cancer (mCRC): Real life experience from Turkey.**
Zengin G., Ozyurt N., Beypinar I., Cinkir H. Y., Bilgin B., Gumusay Ö.

JOURNAL OF CLINICAL ONCOLOGY, no.15, 2018 (SCI-Expanded)

XXXIV. Pazopanib-Induced Hepatotoxicity in an Experimental Rat Model

Cetin B., Yilmaz G. E., Armagan B., AFŞAR B., Demirci U., GÜLBAHAR Ö., Gumusay Ö., Bilgetekin I., ÖZET A., ÜNER A. CHEMOTHERAPY, vol.63, no.1, pp.39-45, 2018 (SCI-Expanded)

XXXV. Central nervous system metastatic epithelial ovarian cancer. Clinical parameters and prognostic factors: a multicenter study of Anatolian Society of Medical Oncology.

Seber S., Turkmen E., Harputoğlu H., Yeşil H., Arpacı E., Menekşe S., Pilancı K., Oruç Z., Taskoylu B. Y., Gumusay Ö., et al.

European journal of gynaecological oncology, vol.38, no.2, pp.227-231, 2017 (SCI-Expanded)

XXXVI. Comparison of three different concurrent chemoradiation regimens for treatment of laryngeal cancer

AYDİL U., AKMANSU M., Gumusay Ö., Bakkal F. K., Yazıcı O., KIZIL Y., Koybasioglu A., Yildiz R., Buyukberber S., Inal E. EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, vol.273, no.9, pp.2795-2803, 2016 (SCI-Expanded)

XXXVII. Crizotinib-induced toxicity in an experimental rat model

Gumusay Ö., Esendagli-Yilmaz G., ÜNER A., Cetin B., Buyukberber S., Benekli M., İLHAN M. N., COŞKUN U., GÜLBAHAR Ö., ÖZET A.

WIENER KLINISCHE WOCHENSCHRIFT, vol.128, no.11-12, pp.435-441, 2016 (SCI-Expanded)

XXXVIII. Factors Influencing Chemotherapy Goal Perception in Newly Diagnosed Cancer Patients

Gumusay Ö., Cetin B., Benekli M., Gurcan G., İLHAN M. N., Bostankolu B., ÖZET A., ÜNER A., COŞKUN U., Buyukberber S.

JOURNAL OF CANCER EDUCATION, vol.31, no.2, pp.308-313, 2016 (SCI-Expanded)

XXXIX. Liver metastases from adenocarcinomas of unknown primary site: management and prognosis in 68 consecutive patients

Algin E., ÖZET A., Gumusay Ö., Yilmaz G., Buyukberber S., COŞKUN U., Baykara M., Cetin B., Yildiz R., Benekli M. WIENER KLINISCHE WOCHENSCHRIFT, vol.128, no.1-2, pp.42-47, 2016 (SCI-Expanded)

XL. The impact of immunohistochemical staining with ezrin-carbonic anhydrase IX and neuropilin-2 on prognosis in patients with metastatic renal cell cancer receiving tyrosine kinase inhibitors

Cetin B., Gonu I. I., Buyukberber S., Afsar B., Gumusay Ö., Algin E., Turan N., ÖZET A., Benekli M., COŞKUN U. TUMOR BIOLOGY, vol.36, no.11, pp.8471-8478, 2015 (SCI-Expanded)

XLI. Small cell neuroendocrine carcinoma of the posterior tongue

Gumusay Ö., Yilmaz G., AYDİL U., ÖZET A., Tufan G., ERDEM O. A., KIZIL Y., Benekli M.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, vol.11, no.3, pp.651-0, 2015 (SCI-Expanded)

XLII. Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites

Gumusay Ö., Benekli M., EKİNCİ Ö., Baykara M., ÖZET A., COŞKUN U., Demirci U., ÜNER A., DURSUN A., Atak E. Y., et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, vol.45, no.5, pp.416-421, 2015 (SCI-Expanded)

XLIII. Factors predicting the development of distant metastases in patients with head and neck squamous cell carcinoma: A retrospective study from a single centre.

Gumusay Ö., Ozet A., Buyukberber S., Baykara M., Coskun U., Cetin B., Uner A., Aydil U., Benekli M.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.20, no.2, pp.521-6, 2015 (SCI-Expanded)

XLIV. Association between survival and maximum standardized uptake value of liver metastases detected by 18-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography in patients with adenocarcinoma of unknown primary origin

Algin E., ÖZET A., Gumusay Ö., Cetin B., AKDEMİR Ü. Ö., Benekli M., COŞKUN U., ÜNER A., ATAY L. Ö., Buyukberber S. ANNALS OF NUCLEAR MEDICINE, vol.28, no.9, pp.891-896, 2014 (SCI-Expanded)

XLV. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology

Kaplan M. A., Isikdogan A., Koca D., Kucukoner M., Gumusay Ö., Yildiz R., Dayan A., Demir L., Geredeli C., Kocer M., et al.

BREAST CANCER, vol.21, no.6, pp.677-683, 2014 (SCI-Expanded)

XLVI. Factors predicting recurrence in patients with grade III glial tumors: impact of adjuvant

temozolomide on recurrence.

Gumusay Ö., Cetin B., Ozet A., Demirci U., Buyukberber S., Coskun U., Algin E., Uner A., Yildiz R., Kurt G., et al.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.19, no.4, pp.1035-40, 2014 (SCI-Expanded)

- XLVII. **Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the Anatolian society of medical oncology**
Gumusay Ö., COŞKUN U., Akman T., Ekinçi A. S., Kocar M., Erceleb O. B., Yazici O., Kaplan M. A., Berk V., Cetin B., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.140, no.1, pp.151-157, 2014 (SCI-Expanded)
- XLVIII. **Association between hemoglobin, calcium, and lactate dehydrogenase variability and mortality among metastatic renal cell carcinoma**
Cetin B., AFŞAR B., DEĞER S. M., IŞIK GÖNÜL İ., Gumusay Ö., ÖZET A., Benekli M., COŞKUN U., Buyukberber S.
INTERNATIONAL UROLOGY AND NEPHROLOGY, vol.46, no.6, pp.1081-1087, 2014 (SCI-Expanded)
- XLIX. **Diagnostic potential of serum direct markers and non-invasive fibrosis models in patients with chronic hepatitis B**
Gumusay Ö., Ozenirler S., ATAK YÜCEL A., Sonmez C., ÖZKAN S., Tuncel A. F., Yilmaz G., AKYOL G.
HEPATOLOGY RESEARCH, vol.43, no.3, pp.228-237, 2013 (SCI-Expanded)
- L. **Biological Subtypes and Survival Outcomes in Breast Cancer Patients with Brain Metastases (Study of the Anatolian Society of Medical Oncology)**
Kaplan M. A., Isikdogan A., Koca D., Kucukoner M., Gumusay Ö., Yildiz R., Dayan A., Demir L., Geredeli C., Kocer M., et al.
ONCOLOGY, vol.83, no.3, pp.141-150, 2012 (SCI-Expanded)
- LI. **Oral Etoposide for Platinum-Resistant and Recurrent Epithelial Ovarian Cancer: a Study by the Anatolian Society of Medical Oncology**
Kucukoner M., Isikdogan A., Yaman S., Gumusay Ö., Unal O., Ulas A., ELKIRAN E. T., Kaplan M. A., Ozdemir N., Inal A., et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.13, no.8, pp.3973-3976, 2012 (SCI-Expanded)
- LII. **Serum levels of advanced oxidation protein products, malonyldialdehyde, and total radical trapping antioxidant parameter in patients with chronic hepatitis C**
Ozenirler S., Erkan G., GÜLBAHAR Ö., Bostankolu Ö., Demirel O. O., Bilgihan A., AKYOL G.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.22, no.1, pp.47-53, 2011 (SCI-Expanded)

Articles Published in Other Journals

- I. **PET/CT, an important imaging modality in the management of sarcoma patients.**
Kayacan E., Üner A., Gümüşay Ö., Akdemir Ü. Ö.
Medicine Science, vol.12, no.4, pp.1-4, 2023 (Peer-Reviewed Journal)
- II. **PD-1 and PD-L1 Blockade plus Chemotherapy in Endometrial Cancer.**
Gümüşay Ö., Çetin B.
N Engl J Med, vol.31, no.389(9), pp.866-867, 2023 (Peer-Reviewed Journal)
- III. **Diagnostic Value of Target Sign and Apparent Diffusion Coefficient Measurements in the Differentiation between Hepatocellular Carcinoma and Liver Metastasis on Diffusion Weighted Magnetic Resonance Imaging**
Albayrak E., Gümüşay Ö., Server S.
JOURNAL OF CONTEMPORARY MEDICINE, vol.13, no.3, pp.473-478, 2023 (Peer-Reviewed Journal)
- IV. **Role of Interleukin-6 Gene Variants in the Development of Oral Squamous Cell Carcinoma**
Gumusay Ö., Yigit S., Nursal A. F., Tekcan A., DAGMURA H., Kuruca N.
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.37, no.4, pp.371-378, 2022 (ESCI)
- V. **Trials of Immunotherapy in Triple Negative Breast Cancer**
Gumusay Ö., Wabl C. A., Rugo H. S.
CURRENT BREAST CANCER REPORTS, vol.13, no.3, pp.171-185, 2021 (ESCI)
- VI. **Genetic Variations of miRNAs and the Risk of Oral Squamous Cell Carcinoma: A Case-control Study**

Yilmaz K., Gumusay Ö., Nursal A. F., Karakus N., Yigit S.

HASEKI TIP BULTENI-MEDICAL BULLETIN OF HASEKI, vol.58, no.3, pp.268-273, 2020 (ESCI)

- VII. **Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology.**
Gumusay Ö., Vitiello P. P., Wabl C., Corcoran R. B., Bardelli A., Rugo H. S.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, vol.40, 2020 (Scopus)
- VIII. **C Deletion in Exon 4 Codon 63 of p53 Gene in Turkish Patients with Oral Squamous Cell Carcinoma**
Tekcan A., Gumusay Ö., Nursal A. F., Yigit S., Yildiz S., Tumer M. K.
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.35, no.2, pp.163-166, 2020 (ESCI)
- IX. **Contralateral Testicular Metastasis of Renal Cell Carcinoma: A Case Report**
Kulukcu E., Kilic S., Parlaktas B. S., Deresoy F. A., Atilgan D., Gumusay Ö., Uluocak N.
EURASIAN JOURNAL OF MEDICINE, vol.51, no.3, pp.310-312, 2019 (ESCI)
- X. **Impact of the Functional VNTR Variants of the Interleukin-1 Receptor Antagonist and Interleukin-4 Genes on Oral Squamous Cell Carcinoma**
Gumusay Ö., Nursal A. F., Yigit S., Tekcan A., Oz T.
ISTANBUL MEDICAL JOURNAL, vol.20, no.3, pp.202-207, 2019 (ESCI)
- XI. **Impact of the functional VNTR variants of the IL-1RA and IL-4 genes on oral squamous cell carcinoma**
GÜMÜŞAY Ö., NURSAL A. F., YİĞİT S., TEKCAN A., Oz T.
Istanbul Medical Journal, vol.0, no.0, 2019 (Peer-Reviewed Journal)
- XII. **Kemiğin dev hücreli tümörü taklit eden primer hiperparatiroidizme bağlı brown tümörü**
DEMİR A. K., KUTLUTÜRK F., GÜL S. S., GÜMÜŞAY Ö.
Journal of Contemporary Medicine, 2018 (Peer-Reviewed Journal)
- XIII. **Kolorektal Kanserlerde Güncel Tedavi Yaklaşımı**
GÜLER AVCI G., GÜMÜŞAY Ö.
Gaziosmanpaşa Üniversitesi Tıp Fakültesi Dergisi, vol.10, no.1, pp.1-7, 2018 (Peer-Reviewed Journal)
- XIV. **Kanserde Tarama ve Erken Tanı**
GÜMÜŞAY Ö., GÜLER AVCI G.
Gaziosmanpaşa Üniversitesi Tıp Fakültesi Dergisi, vol.9, no.4, pp.210-221, 2017 (Peer-Reviewed Journal)
- XV. **The assessment of incidental thyroid lesions on 18F-fluorodeoxyglucose positron emission tomography/computed tomography: A single centre experience**
ALGIN E., ÜNER A., AKDEMİR Ü. Ö., GÜMÜŞAY Ö., KAPUCU Ö., ÖZET A.
Journal of Oncological Sciences, vol.3, no.2, pp.57-61, 2017 (Peer-Reviewed Journal)
- XVI. **Abdominal wall perforation in a patient with recurrent epithelial ovarian cancer after bevacizumab treatment**
ALGIN E., GÜMÜŞAY Ö., DOĞAN M., ÖZET A.
Journal of Oncological Sciences, vol.2, no.2-3, pp.95-96, 2016 (Peer-Reviewed Journal)
- XVII. **Advances of Molecular Targeted Therapy in Gastric Cancer**
Cetin B., Gumusay Ö., Cengiz M., ÖZET A.
Journal of Gastrointestinal Cancer, vol.47, no.2, pp.125-134, 2016 (Scopus)
- XVIII. **Tumor homing to the oral cavity after tooth extraction in a patient with metastatic lung adenocarcinoma: A case report**
GÜMÜŞAY Ö., BOSTANKOLU B., IŞIK GÖNÜL İ., ÖZET A.
Journal of Oncological Science, vol.1, pp.5-7, 2016 (Peer-Reviewed Journal)
- XIX. **EKSTRAKRANİYAL SKALP METASTAZI İLE PREZENTE OLAN NADİR BİR HEPATOSELLÜLER KANSER OLGUSU**
GÜMÜŞAY Ö., DEMİRTAŞ A., ARICI A., GÖKÇE E., YILMAZ E. E., DEMİR A. K., ÖZTÜRK B.
Journal of Contemporary Medicine, vol.0, no.0, 2015 (Peer-Reviewed Journal)
- XX. **HIV Negatif Olguda Skrotal Kaposi Sarkomu**
GÜMÜŞAY Ö., ARSLAN ŞEN T., ALICI Ö., TAKCI Z., ARSLAN KABALAY G. İ., SUHEYLA K. U., ÖZTÜRK B.
Gaziosmanpaşa Üniversitesi Tıp Fakültesi Dergisi, vol.7, no.3, pp.241-245, 2015 (Peer-Reviewed Journal)

- XXI. **Akciğerin Primer Şeffaf Hücreli Şeker Tümörü: Bir Olgu Sunumu**
ALGIN E., GÜMÜŞAY Ö., IŞIK GÖNÜL İ., AKDEMİR Ü. Ö., ÖZET A.
Gaziosmanpaşa Üniversitesi Tıp Fakültesi Dergisi 20157(4):328-334, vol.7, no.4, pp.328-334, 2015 (Peer-Reviewed Journal)
- XXII. **Salvage chemotherapy with weekly paclitaxel for metastatic melanoma**
Ozaslan E., Aksoy A., Gumusay Ö., Arpacı E., Berk V.
Asian Pacific Journal of Cancer Prevention, vol.16, no.6, pp.2581, 2015 (Scopus)
- XXIII. **Second primary tumors in patients with head and neck cancer A retrospective study from a single centre**
GÜMÜŞAY Ö., ÖZET A., BAYKARA M., ÇETİN B., COŞKUN U., BÜYÜKBERBER S., ÜNER A., YILDIZ R., BENEKLİ M.
Türkiye Klinikleri (J Med Sci), vol.34, no.2, pp.262-266, 2014 (Scopus)
- XXIV. **Kanserde monoklonal antikorlarla küre yakın mıyız**
ÖZET A., GÜMÜŞAY Ö.
Tüba Günce, no.47, pp.7-10, 2014 (Non Peer-Reviewed Journal)
- XXV. **Renal Hücreli Kanser Nedeniyle Nefrektomi Yapılan Olguda 16 yıl Sonra Gelişen İzole Beyin Metastazı Solitary Cerebral Metastases from Renal Cell Carcinoma 16 years After Nephrectomy**
GÜMÜŞAY Ö., BENEKLİ M., EFNAN A., ONUR E., ULUOĞLU Ö., ÖNER A. Y., ÖZET A.
Acta Oncologica Turcica, 2014 (Peer-Reviewed Journal)

Books & Book Chapters

- I. **Kanser Tedavisinin Prensipleri**
GÜMÜŞAY Ö.
in: Cecil Essentials of Medicine, Doç. Dr. Meltem Baykara, Editor, Güneş Kitapevi, Ankara, pp.585-591, 2016

Refereed Congress / Symposium Publications in Proceedings

- I. **A phase Ib/II study of eribulin with cyclophosphamide (EC) in patients (pts) with advanced breast cancer (ABC).**
Gumusay Ö., Renslo J. R., Wabl C. A., Chien A. J., Melisko M. E., Majure M. C., Rahmaputri S. D., Moasser M., Park J., Rugo H. S.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 May 2020
- II. **Pazopanib (PZ) plus endocrine therapy as treatment for hormone resistant advanced breast cancer (ABC).**
Gumusay Ö., Majure M. C., Deal T., Renslo J. R., Wabl C. A., Melisko M. E., Chien A. J., Goga A., Moasser M., Park J., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 May 2020
- III. **Can Target Sign Detected by DWI Be Used as an Assisting MRI Marker in the Differential Diagnosis of Liver Metastases?**
ALBAYRAK E., GÜMÜŞAY Ö.
XVI. Balkan Congress of Radiology, 4 - 06 October 2018
- IV. **Associations of Between IL-6 Gene Variation and Oral Squamous Cell Carcinoma (OSCC)**
NURSAL A. F., YİĞİT S., TEKCAN A., GÜMÜŞAY Ö.
WITAM-2018: International Congress on the World of Technology and Advanced Materials, Kırşehir, Turkey, 21 - 23 September 2018
- V. **Oral Kanserli Hastalarda İnterleukin 6 Geni (IL6) Polimorfizmleri**
YİĞİT S., NURSAL A. F., GÜMÜŞAY Ö., KARAKUŞ N., Yılmaz K., Öz T.
International Eurasian Conference on Biological and Chemical Sciences, 26 - 27 April 2018
- VI. **Oral kanserli hastalarda Interlökin-4 VNTR polimorfizmi**
GÜMÜŞAY Ö., NURSAL A. F., YİĞİT S., TEKCAN A., Yılmaz K., KISMALI G.

INTERNATIONAL EURASIAN CONFERENCE ON BIOLOGICAL AND CHEMICAL SCIENCES, 26 - 27 April 2018

VII. **Oral kanserli hastalarda Interlökin- 6 (IL-6) gen polimorfizmleri**

YİĞİT S., NURSAL A. F., GÜMÜŞAY Ö., KARAKUŞ N., Yılmaz E., Öz T.

INTERNATIONAL EURASIAN CONFERENCE ON BIOLOGICAL AND CHEMICAL SCIENCES, 26 - 27 April 2018

VIII. **TÜRKİYE'DE METASTATİK MEME KANSERİNDE HER2 HEDEFLİTEDAVIDE PERTUZUMAB KULLANIMI ERKEN DÖNEM GÜVENLİLİKVERİLERİ**

ESİN E., ÇAKMAK ÖKSÜZOĞLU Ö. B., SAKİN A., YILDIRIM N., ÇABUK D., KARAAĞAÇ M., OLGUN P., ŞAKALAR T., AKTAŞ B. Y., DEĞİRMENCİOĞLU S., et al.

7. TÜRK TIBBİ ONKOLOJİ KONGRESİ, Turkey, 21 - 24 March 2018

IX. **Liver metastases from adenocarcinomas of unknown primary site Management and prognosis in 68 consecutive patients**

EFNAN A., ÖZET A., GÜMÜŞAY Ö., YILMAZ G., BÜYÜKBERBER S., COŞKUN U., MELTEM B., ÇETİN B., YILDIZ R., BENEKLİ M.

ECCO-ESMO-ESTRO 2015, 25 - 29 September 2015

X. **The assessment of incidental thyroid lesions on 18F Flourodeoxyglucose positron emission tomography computed tomography A single centre experience**

EFNAN A., BENEKLİ M., AKDEMİR Ü. Ö., GÜMÜŞAY Ö., COŞKUN U., YILDIZ R., KAPUCU Ö., BÜYÜKBERBER S.

ECCO-ESMO-ESTRO 2015, 25 - 29 September 2015

XI. **Deneyisel Rat Modelinde Crizotinib İlişkili Toksikite**

GÜMÜŞAY Ö., YILMAZ G., ÜNER A., ÇETİN B., BÜYÜKBERBER S., BENEKLİ M., İLHAN M. N., COŞKUN U., GÜLBAHAR Ö., ÖZET A.

12. Ulusal Tıbbi Onkoloji Kongresi, 2015, Turkey, 17 - 19 September 2015

XII. **Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites**

Gumusay Ö., Benekli M., EKİNCİ Ö., Baykara M., ÖZET A., Coskun U., Uner A., Dursun A., Atak E. Y., Buyukberber S. Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 15 - 17 January 2015

XIII. **Predictive factors for the development of brain metastases in patients with malignant melanoma: A study by the Anatolian Society of Medical Oncology**

Gumusay Ö., Akman T., Ekinci A. S., Kocar M., Erceleb O. B., Kaplan M. A., Yazici O., Berk V., ÇETİN B. E., COŞKUN U.

European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, Amsterdam, Netherlands, 27 September - 01 October 2013

XIV. **Clinical significance of Ezrin and Neuropilin-2 expression in advanced renal cell carcinoma**

ÇETİN B. E., IŞIK GÖNÜL İ., Buyukberber S., Afsar B., Gumusay Ö., Benekli M., COŞKUN U.

European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, Amsterdam, Netherlands, 27 September - 01 October 2013

XV. **The effects of variability of mean erythrocyte corpuscular volume (MCV) in patients with advanced stage gastrointestinal stromal tumor (GIST) using imatinib on progression free survival**

ÇETİN B. E., TAŞTEKİN D., Aktas B., Guler T., Kaplan M. A., Berk V., Gumusay Ö., Dane F., ÖZKAN M., Benekli M.

European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, Amsterdam, Netherlands, 27 September - 01 October 2013

XVI. **Lapatinib or trastuzumab? Which anti-HER2 treatment is more effective in the treatment of patients with HER2-positive breast cancer with brain metastases? An Anatolian Society of Medical Oncology Study**

Kaplan M. A., Isikdogan A., Koca D., Kucukoner M., Gumusay Ö., Yildiz R., Oztop I., Demir L., Geredeli C., Kocer M., et al.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012

Supported Projects

Gümüşay Ö., Project Supported by Private Organizations in Other Countries, A Phase III, Randomized, Double-Blind,

Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative 23 Therapy, 2023 - 2026

Gümüřay Ö., Company, Erken Evre Meme Kanserinde Prognozu Belirlemede CanAssist Breast Testi ile Oncotype Dx/ MammaPrint Konkordansının Belirlenmesi, 2022 - 2025

Gümüřay Ö., Project Supported by Private Organizations in Other Countries, A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients who are not Candidates for PD- 1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast02), 2022 - 2025

Gümüřay Ö., Project Supported by Private Organizations in Other Countries, A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) (, 2021 - 2025

Gümüřay Ö., Project Supported by Private Organizations in Other Countries, A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With HER2-positive Metastatic Breast Cancer (DESTINY-Breast07), 2020 - 2025

Gümüřay Ö., Project Supported by Private Organizations in Other Countries, EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (ClinicalTrials.gov identifier, 2019 - 2024

Gümüřay Ö., TUBITAK Project, Analysis of P53 gene mutations in patients with oral squamous cell carcinoma. Scientific research project supported by Higher Education Institutions, , 2017 - 2024

Gümüřay Ö., Project Supported by Private Organizations in Other Countries, A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo in Patients With HER2-Positive and PD-L1-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab- (+/- Pertuzumab) and Taxane-Based Therapy (KATE3) (ClinicalTrials.gov identifier: NCT04740918), 2021 - 2023

Gümüřay Ö., Project Supported by Public Organizations in Other Countries, A Phase Ib/II Study of Eribulin in Combination with Cyclophosphamide in Patients with Solid Tumor Malignancies. , 2012 - 2021

Gümüřay Ö., Universities of Other Countries Supported Project, Reversing Hormone Resistance in Advanced Breast Cancer with Pazopanib. Phase II trial, 2011 - 2020

Gümüřay Ö., Project Supported by Other Private Institutions, Regorafenib in subjects with metastatic colorectal cancer (mCRC) who have progressed after Standard therapy in Turkey, Phase III,, 2013 - 2018

Gümüřay Ö., Project Supported by Other Private Institutions, Epidemiological study including evaluation of HER2 status in gastric and gastroesophageal junction cancer tumor. Epidemiologic study, 2012 - 2016

Activities in Scientific Journals

FRONTIERS IN ONCOLOGY, Evaluation Committee Member, 2021 - Continues

Memberships / Tasks in Scientific Organizations

Türk Tıbbi Onkoloji Derneđi Yeterlilik Kurulu Üyeliđi, Member of Science Committee, 2021 - Continues, Turkey

Türk Tıbbi Onkoloji Derneđi Uluslararası İliřkiler Komisyon Üyeliđi, Member, 2021 - 2023, Turkey

Türk Tıbbi Onkoloji Derneđi CESMA Deleđeliđi, U.E.M.S. (European Union of Medical Specialists) , Member, 2021 - 2023, Turkey